BUY Marksans Pharma Limited — Axis Securities
byAxis SecuritiesHorizon: NA (inferred 1 year)31 Aug 2026via Institutional / Brokerage Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Long-term trend bullish — 200-day average rising over the past quarter
Technicals · trend·4 Sept · 2d ago
2 advisors have active short-term BUY calls on this stock
Advisor consensus · adjacent horizon·18 Aug · 3w ago
Marksans Pharma shares rally over 9% after Q1 profit spikes 174% YoY to Rs 159 crore
NewsEt-Markets·12 Aug · 4w ago
Marksans Pharma Q1 Results: Shares jump 11% after profit nearly triples, margin expands
NewsCnbc-Tv18·12 Aug · 4w ago
Marksans Pharma reported record Q1FY27 results with all-time high profitability and cash balance crossing ₹1,000 crore. EBITDA rose 113% YoY to ₹213 crore, and PAT grew 174% YoY to ₹159 crore. UK & Eu
NSE · Press Release·12 Aug · 4w ago
Mazagon Dock, Marksans Pharma, NIIT Learning Systems, Natco Pharma Dividends: Last Day To Buy Shares To Qualify
NewsNdtv-Profit·19 Aug · 3w ago
Marksans Pharma Ltd announced that its Board of Directors approved the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026, during a meeting held on August 12
BSE · Board Meeting·12 Aug · 4w ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.